Understanding the Condition
Depression and anxiety are prevalent and severe mood disorders that significantly impact millions of individuals worldwide. Depression is characterized by persistent sadness, loss of interest in previously enjoyed activities, and cognitive and physical impairment. Anxiety involves excessive fear and worry that disrupt daily life. Both conditions frequently co-occur, compounding their impact on quality of life and functioning.
Traditional pharmacological treatments such as SSRIs often provide incomplete relief and carry numerous side effects including weight gain, sexual dysfunction, and emotional blunting. Long-term SSRI use can lead to dependency and heightened risks of suicidal ideation. potentially worsening the original condition rather than resolving it. Many patients cycle through multiple medications without finding lasting relief because the root causes remain unaddressed.
MindScape addresses these failures through a protocol that begins before the primary ibogaine session. Depression patients receive ibogaine TA booster doses prior to the HCl flood, initiating serotonergic, dopaminergic, and glutamatergic recalibration simultaneously — a broader neurochemical intervention than purified HCl alone achieves. Noribogaine's inhibition of the serotonin transporter begins shifting receptor sensitivity gradually, particularly important for patients whose serotonin systems have been dysregulated by the condition itself or by years of prior SSRI use. This progressive approach minimizes cardiovascular stress while allowing mood-regulating neurotransmitter systems to begin recalibrating before the primary therapeutic session amplifies the antidepressant effect.
Conditions We Treat
Ibogaine resets the brain's neurochemical balance, particularly affecting dopamine and serotonin pathways essential for mood regulation. Patients frequently describe a lifting of the depressive weight that medications failed to touch. and an emotional clarity that persists well beyond the treatment itself.
For those who have exhausted conventional options, ibogaine represents a fundamentally different mechanism of action. Rather than modulating a single receptor, it resets the entire neurochemical architecture, offering hope where SSRIs, SNRIs, and even ECT have not delivered lasting relief.
Anxiety involves hyperactivation of the stress response and dysregulation of the autonomic nervous system. Ibogaine's modulation of the kappa-opioid and serotonin systems reduces the chronic hyperarousal underlying generalized anxiety, often producing a calm that patients describe as unprecedented in their experience.
Roughly half of all addiction cases involve co-occurring depression or anxiety. Ibogaine treats both simultaneously. interrupting the substance dependency cycle while addressing the mood disorder that often underlies and perpetuates it. A single protocol can accomplish what separate treatments have not.
The Mechanism
Ibogaine operates by resetting the brain's neurochemical balance, particularly affecting dopamine and serotonin. neurotransmitters essential for mood regulation and emotional stability. It also upregulates Glial Cell Line-Derived Neurotrophic Factor (GDNF), which plays a critical role in neuronal survival and growth, facilitating the brain's capacity to reorganize and repair itself. This enhancement of neuroplasticity is vital for recovering from the neural damage caused by chronic depression and anxiety.
A pivotal aspect of ibogaine's therapeutic effect is its metabolite noribogaine, which remains active in the body for several months post-treatment. Noribogaine inhibits serotonin reuptake, elevates serotonin levels associated with improved mood, and modulates the kappa-opioid receptor to reduce stress and dysphoria. We combine ibogaine therapy with NAD+ infusions and 5-MeO-DMT to create a synergistic protocol that amplifies neuroplasticity, accelerates healing, and addresses the psychological layers of depression that neurochemistry alone cannot reach.
Treatment Journey
Your journey begins with an honest conversation. Our team reviews your history, current medications (including SSRIs requiring careful taper planning), prior treatments, and personal goals. with no judgment and no pressure.
Guests undergo thorough medical and psychological assessment including EKG, complete bloodwork, and liver panel. SSRI discontinuation protocols are carefully managed to ensure a safe transition into ibogaine therapy.
Our medical team and psychologists design a customized dosing plan. determining whether a microdose sequence or macrodose approach best serves your particular presentation of depression, anxiety, or both.
Arrive at our intimate sanctuary on Cozumel Island. The ibogaine experience unfolds over 12 to 24 hours under continuous physician supervision, often producing profound introspective insights that illuminate the psychological roots of the depression.
Post-treatment integration is where insights become lasting change. We provide extensive support to help you process your experience, apply therapeutic realizations to daily life, and build the structures that sustain long-term mental health.
Common Questions
Program Investment
Psilocybin Program
$4,000
5-day, 4-night psilocybin-assisted therapy retreat. Snorkeling, beach, and cenote experiences included.
Ibogaine Protocol
$7,500
10 to 14 day all-inclusive ibogaine program. Full neurochemical reset and integration support.
All pricing includes accommodations, meals, medical supervision, pre-treatment preparation, NAD+ infusions, 5-MeO-DMT therapy, and 90-day integration support. No hidden fees.
If antidepressants have not given you the life you want, speak with our medical team. We will tell you honestly whether ibogaine therapy is appropriate for your situation.
Request a Confidential ConsultationLatest Research & News
Feb 26, 2026
A woman suffering from treatment-resistant depression for nineteen years walked into a clinical trial at Imperial Colleg...
Read Article →Feb 26, 2026
The field of psychedelic medicine took another significant step forward this week. A Phase II clinical trial published t...
Read Article →Feb 21, 2026
Introduction If you're taking Effexor (venlafaxine) and considering ibogaine treatment , understanding the critical safe...
Read Article →Feb 18, 2026
Prozac (fluoxetine) has been one of the most prescribed antidepressants since the 1980s. If you're taking Prozac and exp...
Read Article →
